{"id":6087,"date":"2023-02-21T07:30:00","date_gmt":"2023-02-21T07:30:00","guid":{"rendered":"https:\/\/realheart.se\/mfn_news\/professor-bart-meyns-strengthens-realhearts-advisory-board\/"},"modified":"2023-02-21T07:30:00","modified_gmt":"2023-02-21T07:30:00","slug":"professor-bart-meyns-strengthens-realhearts-advisory-board","status":"publish","type":"mfn_news","link":"https:\/\/realheart.se\/sv\/mfn_news\/professor-bart-meyns-strengthens-realhearts-advisory-board\/","title":{"rendered":"Professor Bart Meyns Strengthens Realheart’s Advisory Board"},"content":{"rendered":"
Press Release 21 February, 2023<\/p>\n

The Swedish company Realheart, which is developing the world's first four-chamber artificial heart, is further strengthening its expertise when Belgian surgeon Bart Meyns joins the company's medical advisory board. Dr Meyns is a Professor at the University of Leuven in Belgium and is also leading Realheart's surgical team in the ongoing animal study.<\/strong><\/div>\n

Bart Meyns has been President of both the European Society of Artificial Organs, ESAO, and the International Society of Mechanical Circulatory Support, ISMCS, of which Realheart's CEO, Dr Ina Laura Perkins, is a board member. He has also published more than 350 peer-reviewed articles in scientific journals.<\/span><\/span><\/span><\/p>\n

He is currently head of the Department of Cardiac Surgery at the University Hospital UZ Leuven and a professor at the Faculty of Medicine at KU Leuven. Professor Bart Meyns is part of the surgical team performing the implantations in Realheart's ongoing animal study, paving the way for clinical trials scheduled to begin in 2024.<\/span><\/span><\/span><\/p>\n

''Bart Meyns is one of the most skilled and experienced cardiac surgeons available for heart pump implantations. He has been invaluable at the operating table during our animal trials, and I am delighted to be able to bring him even closer to us. His knowledge will be a very valuable addition to our competent medical board'' says Ina Laura Perkins, CEO of Realheart.<\/span><\/span><\/span><\/p>\n

The medical advisory board also includes Professors Henrik Casimir Ahn, Robert D. Dowling and Zolt\u00e1n Szab\u00f3 and Dr Ulf Kjellman.<\/span><\/span><\/span><\/p>\n

\n

For more information please contact:<\/span><\/span><\/strong><\/span><\/p>\n

Ina Laura Perkins, CEO<\/span><\/span><\/p>\n

Phone: +46(0)70 406 49 21\u00a0<\/span><\/span><\/p>\n

E-mail: inalaura.perkins@realheart.se<\/span><\/span><\/p>\n

Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se<\/a><\/p>\n<\/div>\n

\n

Scandinavian Real Heart AB develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. Realheart<\/em><\/span><\/span>\u00ae<\/span><\/span><\/span><\/em> TAH has a patented design that resembles that of the natural human heart. The artificial heart consists of a four-chamber system (two atria and two ventricles) designed to generate a physiological blood flow pattern that mimics the body's natural circulation.\u00a0<\/em><\/span><\/span>A unique concept in the medical technology world.<\/span><\/span><\/span><\/em><\/p>\n<\/div>\n